AU2002213174A1 - Treatment of apoptotic cell death - Google Patents

Treatment of apoptotic cell death

Info

Publication number
AU2002213174A1
AU2002213174A1 AU2002213174A AU1317402A AU2002213174A1 AU 2002213174 A1 AU2002213174 A1 AU 2002213174A1 AU 2002213174 A AU2002213174 A AU 2002213174A AU 1317402 A AU1317402 A AU 1317402A AU 2002213174 A1 AU2002213174 A1 AU 2002213174A1
Authority
AU
Australia
Prior art keywords
treatment
cell death
apoptotic cell
apoptotic
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002213174A
Inventor
Massaharu Akao
Eduardo Marban
Brian O'rourke
Andreas Ohler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Publication of AU2002213174A1 publication Critical patent/AU2002213174A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002213174A 2000-10-13 2001-10-15 Treatment of apoptotic cell death Abandoned AU2002213174A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24026700P 2000-10-13 2000-10-13
US60240267 2000-10-13
PCT/US2001/031992 WO2002030411A2 (en) 2000-10-13 2001-10-15 Treatment of apoptotic cell death

Publications (1)

Publication Number Publication Date
AU2002213174A1 true AU2002213174A1 (en) 2002-04-22

Family

ID=22905851

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002213174A Abandoned AU2002213174A1 (en) 2000-10-13 2001-10-15 Treatment of apoptotic cell death

Country Status (3)

Country Link
US (1) US6521617B2 (en)
AU (1) AU2002213174A1 (en)
WO (1) WO2002030411A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100492252B1 (en) * 2002-08-09 2005-05-30 한국화학연구원 Benzopyran derivatives substituted with secondary amines including imidazole and their preparation
CN1964630A (en) * 2003-02-13 2007-05-16 耶希瓦大学艾伯塔·爱恩斯坦医学院 Regulation of food intake and glucose production by modulation of long-chain fatty acyl-coa levels in the hypothalamus
ES2342090T3 (en) 2004-08-25 2010-07-01 Essentialis, Inc. PHARMACEUTICAL FORMULATIONS OF OPENING AGENTS OF POTASSIUM CHANNELS DEPENDENT ON ATP AND USES OF THE SAME.
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
CN101868239B (en) 2006-01-05 2015-06-10 伊森舍丽斯有限公司 Salts of potassium ATP channel openers and uses thereof
US20090076095A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched nicorandil
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
EP2422787A1 (en) * 2010-08-17 2012-02-29 Neurotec Pharma, S.L. Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6183948B1 (en) * 1998-04-15 2001-02-06 Johns Hopkins University Methods to identify compounds affecting mitochondria
WO2001030332A2 (en) * 1999-10-22 2001-05-03 Wake Forest University Methods of protecting neuronal function

Also Published As

Publication number Publication date
WO2002030411A2 (en) 2002-04-18
US6521617B2 (en) 2003-02-18
WO2002030411A8 (en) 2002-07-11
US20020091144A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
AU2001291859A1 (en) Use of copolycarbonates
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AUPQ544900A0 (en) Treatment of cellulosic material
AU2001245965A1 (en) Large body stretcher
AUPQ877300A0 (en) Topical treatment of skin
AU2001259702A1 (en) Tissue regrafting
AU2001233208A1 (en) Human sulfatases
AUPR074500A0 (en) Treatment of t cell disorders
AU2002231206A1 (en) Treatment of depression
AU2001260834A1 (en) The treatment of herpes
AU2002213174A1 (en) Treatment of apoptotic cell death
AU2002216223A1 (en) Preservation of cells
AU2002227925A1 (en) Human beta-defensin-3
AU2001257138A1 (en) Neutralization of reactive elements
AU2001245414A1 (en) Treatment of allergies
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU2002214868A1 (en) Therapeutic oligonucleotides of reduced toxicity
AU2001274022A1 (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AU4432001A (en) Trityl-type compounds and their use
AU2001281950A1 (en) Regulation of human thimet oligopeptidase-like enzyme
AU2002250668A1 (en) Crushing body comprising concave portions
AU2001281465A1 (en) Treatment of rosacea
AU2001269095A1 (en) Regulation of human caspase-1-like protease
AU2001258330A1 (en) New uses of imidazolylmethyl-pyridines
AU2001253560A1 (en) Methods of treatment